Treatment effects on body weight. Average body weights (kg) are shown at 4-week intervals over the 24-week, blinded study period for all patients who received either canakinumab (red line) or placebo (blue line) (A). Post hoc MMRM analysis was applied to study participants aged <18 years and segregated by baseline BMI percentile of <20th percentile (B), 20th to 80th percentile (C), and >80th percentile (D). Standard error of the means (A) and standard deviations (B-D) are shown, and a dotted horizontal line references normalized baseline levels.